Dual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier?
{{output}}
With majority of ischemic strokes attributable to atherothrombosis and many being predictable after transient ischemic attacks (TIA), the role of early secondary prevention with antiplatelet agents is under renewed investigation. Prior major clinical trials of... ...
